Barclays PLC lessened its position in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 24.9% in the third quarter, Holdings Channel.com reports. The firm owned 133,011 shares of the biotechnology company’s stock after selling 44,209 shares during the period. Barclays PLC’s holdings in Veracyte were worth $2,968,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. bought a new position in shares of Veracyte during the first quarter worth about $27,000. Point72 Hong Kong Ltd bought a new position in shares of Veracyte during the 1st quarter worth approximately $33,000. International Assets Investment Management LLC acquired a new stake in shares of Veracyte in the third quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Veracyte by 96.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,862 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 913 shares in the last quarter. Finally, CWM LLC boosted its holdings in Veracyte by 533.0% during the third quarter. CWM LLC now owns 2,146 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,807 shares during the last quarter.
Analyst Ratings Changes
Several equities research analysts have commented on the stock. The Goldman Sachs Group cut their price target on shares of Veracyte from $37.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, October 20th. Needham & Company LLC reduced their price target on Veracyte from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. William Blair reaffirmed an “outperform” rating on shares of Veracyte in a research report on Wednesday, November 8th. Finally, Morgan Stanley cut their price objective on Veracyte from $23.00 to $22.00 and set an “underweight” rating for the company in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.
Veracyte Stock Up 3.7 %
VCYT opened at $26.52 on Tuesday. Veracyte, Inc. has a 12-month low of $19.52 and a 12-month high of $30.52. The business has a 50 day moving average of $26.58 and a 200-day moving average of $24.94. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -38.43 and a beta of 1.68.
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
- Five stocks we like better than Veracyte
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- 3 attractive stocks that insiders are buying
- What Is WallStreetBets and What Stocks Are They Targeting?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.